Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database.

A. Blom Fily, Philippe Saïag, Marie-Noelle Solbes et al.|Journal of Clinical Oncology|2023

Cited by 3